Macular Degeneration: Alpeza-Dunato Z

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 2 Articles   Help
A digest of articles written 1999 and later, on the topic "Macular Degeneration," originating from Planet Earth —» Alpeza-Dunato Z.  Display:  All Citations ·  All Abstracts
1 Clinical Conference Intravitreal bevacizumab for the management of age-related macular degeneration. 2008

Kovacević D, Caljkusić-Mance T, Misljenović T, Mikulicić M, Alpeza-Dunato Z. · Department of Ophthalmology, University Hospital Rijeka, Rijeka, Croatia. · Coll Antropol. · Pubmed #19137998 No free full text.

Abstract: The aim of this study is to report short-term effect of the treatment of "wet" ARMD (age-related macular degeneration) with intravitreal bevacizumab (Avastin). Prospective study included 36 patients (36 eyes) with "wet' form of ARMD. All patients were over 60 year old (22 female, 14 male). Changes of macula included minimally classic CNV (choroidal neovascularisation) (24), occult subfoveal CNV (10) and first stage of cicatrial CNV (2). Bevacizumab 1.25 mg was administered intravitreally through pars plana using a 27-gauge needle. Patients had no previous eye treatment. Ophthalmic exam before and after the treatment included: Snellen VA (visual acuity) and examination including measurement of IOP (intraocular pressure), FA (fluorescein angiography) and interview with patients. After 4-6 weeks 28 (78%) patients had significant improvement of VA. Median VA improved from 0.083 to 0.200 (p<0.01). Eight patients (22%) had no significant improvement in VA but three of them reported to see more light. FA showed complete resolution of macular edema in 6 patients (17%), partially resolved in 23 patients (64%) and no change in 7 patients (19%). No systemic side-effect was found. Short-term results suggest that intravitreally administered bevacizumab is well tolerated treatment for ARMD with very high number of patients showing improvement in VA.

2 Article Dental inflammation and central retinitis--it is important to protect the retina from the harmful sunlight. 2008

Sepić-Bilić T, Zeneral-Zuza I, Alpeza-Dunato Z, Njirić S, Vojniković B. · Department of Otorhinolaryngology-Audiology, University Hospital Rijeka, Rijeka, Croatia. · Coll Antropol. · Pubmed #19138005 No free full text.

Abstract: During 3-year study of 73 patients with dental inflammation, sinusitis, otitis and 5 cases with granuloma, in 9 cases we observed the development of central retinitis. All patients were medicated with the same antibiotics and parabulbar depo of Prednisolonacetate. To 50% of these patients, we suggested eye protection with Yellow Medical filters during two months. In the first group with medication we observed better vision in 69%, but in the second group with eye protection with Yellow Medical filters we observed normalization of vision in 100%.